The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Respiratory Diseases Drugs Market Research Report 2025
Synopsis
Respiratory drug is a term used to describe a wide variety of medicines used to relieve, treat, or prevent respiratory diseases such as asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), or pneumonia.
The global Respiratory Diseases Drugs market was valued at US$ 45700 million in 2023 and is anticipated to reach US$ 67930 million by 2030, witnessing a CAGR of 5.8% during the forecast period 2024-2030.
Growth in this market is mainly driven by increasing preference of pulmonary route of drug delivery, increasing technological developments in the form of smart/digital inhalers and rising incidences of respiratory diseases such as COPD, asthma, and cystic fibrosis.
This report aims to provide a comprehensive presentation of the global market for Respiratory Diseases Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Respiratory Diseases Drugs.
Report Scope
The Respiratory Diseases Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Respiratory Diseases Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Respiratory Diseases Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
AstraZeneca
Boehringer Ingelheim
Vertex
Roche
Novartis
Teva
Chiesi
Viatris
Sumitomo Dainippon
Merck
Beximco
Segment by Type
Inhalable & Nasal Spray
Oral
Others
Segment by Application
Hospital
Retail Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Respiratory Diseases Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Respiratory drug is a term used to describe a wide variety of medicines used to relieve, treat, or prevent respiratory diseases such as asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), or pneumonia.
The global Respiratory Diseases Drugs market was valued at US$ 45700 million in 2023 and is anticipated to reach US$ 67930 million by 2030, witnessing a CAGR of 5.8% during the forecast period 2024-2030.
Growth in this market is mainly driven by increasing preference of pulmonary route of drug delivery, increasing technological developments in the form of smart/digital inhalers and rising incidences of respiratory diseases such as COPD, asthma, and cystic fibrosis.
This report aims to provide a comprehensive presentation of the global market for Respiratory Diseases Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Respiratory Diseases Drugs.
Report Scope
The Respiratory Diseases Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Respiratory Diseases Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Respiratory Diseases Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
AstraZeneca
Boehringer Ingelheim
Vertex
Roche
Novartis
Teva
Chiesi
Viatris
Sumitomo Dainippon
Merck
Beximco
Segment by Type
Inhalable & Nasal Spray
Oral
Others
Segment by Application
Hospital
Retail Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Respiratory Diseases Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Respiratory Diseases Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Inhalable & Nasal Spray
1.2.3 Oral
1.2.4 Others
1.3 Market by Application
1.3.1 Global Respiratory Diseases Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Respiratory Diseases Drugs Market Perspective (2019-2030)
2.2 Respiratory Diseases Drugs Growth Trends by Region
2.2.1 Global Respiratory Diseases Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Respiratory Diseases Drugs Historic Market Size by Region (2019-2024)
2.2.3 Respiratory Diseases Drugs Forecasted Market Size by Region (2025-2030)
2.3 Respiratory Diseases Drugs Market Dynamics
2.3.1 Respiratory Diseases Drugs Industry Trends
2.3.2 Respiratory Diseases Drugs Market Drivers
2.3.3 Respiratory Diseases Drugs Market Challenges
2.3.4 Respiratory Diseases Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Respiratory Diseases Drugs Players by Revenue
3.1.1 Global Top Respiratory Diseases Drugs Players by Revenue (2019-2024)
3.1.2 Global Respiratory Diseases Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Respiratory Diseases Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Respiratory Diseases Drugs Revenue
3.4 Global Respiratory Diseases Drugs Market Concentration Ratio
3.4.1 Global Respiratory Diseases Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Respiratory Diseases Drugs Revenue in 2023
3.5 Respiratory Diseases Drugs Key Players Head office and Area Served
3.6 Key Players Respiratory Diseases Drugs Product Solution and Service
3.7 Date of Enter into Respiratory Diseases Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Respiratory Diseases Drugs Breakdown Data by Type
4.1 Global Respiratory Diseases Drugs Historic Market Size by Type (2019-2024)
4.2 Global Respiratory Diseases Drugs Forecasted Market Size by Type (2025-2030)
5 Respiratory Diseases Drugs Breakdown Data by Application
5.1 Global Respiratory Diseases Drugs Historic Market Size by Application (2019-2024)
5.2 Global Respiratory Diseases Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Respiratory Diseases Drugs Market Size (2019-2030)
6.2 North America Respiratory Diseases Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Respiratory Diseases Drugs Market Size by Country (2019-2024)
6.4 North America Respiratory Diseases Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Respiratory Diseases Drugs Market Size (2019-2030)
7.2 Europe Respiratory Diseases Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Respiratory Diseases Drugs Market Size by Country (2019-2024)
7.4 Europe Respiratory Diseases Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Respiratory Diseases Drugs Market Size (2019-2030)
8.2 Asia-Pacific Respiratory Diseases Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Respiratory Diseases Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Respiratory Diseases Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Respiratory Diseases Drugs Market Size (2019-2030)
9.2 Latin America Respiratory Diseases Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Respiratory Diseases Drugs Market Size by Country (2019-2024)
9.4 Latin America Respiratory Diseases Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Respiratory Diseases Drugs Market Size (2019-2030)
10.2 Middle East & Africa Respiratory Diseases Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Respiratory Diseases Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Respiratory Diseases Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Detail
11.1.2 GSK Business Overview
11.1.3 GSK Respiratory Diseases Drugs Introduction
11.1.4 GSK Revenue in Respiratory Diseases Drugs Business (2019-2024)
11.1.5 GSK Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Detail
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Respiratory Diseases Drugs Introduction
11.2.4 AstraZeneca Revenue in Respiratory Diseases Drugs Business (2019-2024)
11.2.5 AstraZeneca Recent Development
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Company Detail
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Respiratory Diseases Drugs Introduction
11.3.4 Boehringer Ingelheim Revenue in Respiratory Diseases Drugs Business (2019-2024)
11.3.5 Boehringer Ingelheim Recent Development
11.4 Vertex
11.4.1 Vertex Company Detail
11.4.2 Vertex Business Overview
11.4.3 Vertex Respiratory Diseases Drugs Introduction
11.4.4 Vertex Revenue in Respiratory Diseases Drugs Business (2019-2024)
11.4.5 Vertex Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Respiratory Diseases Drugs Introduction
11.5.4 Roche Revenue in Respiratory Diseases Drugs Business (2019-2024)
11.5.5 Roche Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Respiratory Diseases Drugs Introduction
11.6.4 Novartis Revenue in Respiratory Diseases Drugs Business (2019-2024)
11.6.5 Novartis Recent Development
11.7 Teva
11.7.1 Teva Company Detail
11.7.2 Teva Business Overview
11.7.3 Teva Respiratory Diseases Drugs Introduction
11.7.4 Teva Revenue in Respiratory Diseases Drugs Business (2019-2024)
11.7.5 Teva Recent Development
11.8 Chiesi
11.8.1 Chiesi Company Detail
11.8.2 Chiesi Business Overview
11.8.3 Chiesi Respiratory Diseases Drugs Introduction
11.8.4 Chiesi Revenue in Respiratory Diseases Drugs Business (2019-2024)
11.8.5 Chiesi Recent Development
11.9 Viatris
11.9.1 Viatris Company Detail
11.9.2 Viatris Business Overview
11.9.3 Viatris Respiratory Diseases Drugs Introduction
11.9.4 Viatris Revenue in Respiratory Diseases Drugs Business (2019-2024)
11.9.5 Viatris Recent Development
11.10 Sumitomo Dainippon
11.10.1 Sumitomo Dainippon Company Detail
11.10.2 Sumitomo Dainippon Business Overview
11.10.3 Sumitomo Dainippon Respiratory Diseases Drugs Introduction
11.10.4 Sumitomo Dainippon Revenue in Respiratory Diseases Drugs Business (2019-2024)
11.10.5 Sumitomo Dainippon Recent Development
11.11 Merck
11.11.1 Merck Company Detail
11.11.2 Merck Business Overview
11.11.3 Merck Respiratory Diseases Drugs Introduction
11.11.4 Merck Revenue in Respiratory Diseases Drugs Business (2019-2024)
11.11.5 Merck Recent Development
11.12 Beximco
11.12.1 Beximco Company Detail
11.12.2 Beximco Business Overview
11.12.3 Beximco Respiratory Diseases Drugs Introduction
11.12.4 Beximco Revenue in Respiratory Diseases Drugs Business (2019-2024)
11.12.5 Beximco Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
